FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with ...
Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. Despite the phase ...
Early and Consistent Decreases in P-tau 217 Plasma Levels Were Associated with Improvements in Cognition, Function, and Brain Atrophy Measures MCI Subjects Receiving Valiltramiprosate Showed ...
Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m²/yr from baseline 73% of patients maintained albuminuria ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results